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Background: IMRT provides highly conformal dose distributions creating non uniform spatial
intensity using different segments in the beam.
Material & Methods and Results: Different retrospective studies have shown a high capability of
IMRT  to treat tumours close to the base of skull. Prospective studies have shown a decrease
in  xerostomia compared with conventional 3D conformal treatment (3DCRT). Modulation of
intensity is performed by the movement of the multileaf collimator (MLC) that can deliver
the  radiation in different ways, such as static ﬁeld segments, dynamic ﬁeld segments and
rotational delivery (arc therapy and tomotherapy). There are slight differences among theherapy
ead and neck cancer
otational therapy
different techniques in terms of homogeneity, dose conformity and treatment delivery time.
Conclusions: The best method to deliver IMRT will depend on multiple factors such as deliv-
erability, practicality, user training and plan quality.
and Comotherapy ©  2013 Greater Pol
.  Background
adiotherapy (RT) is the cornerstone of treatment for locally
dvanced head and neck cancer (LAHNC). The main goal
f radiotherapy is to provide the maximum loco-regional
ontrol with the minimum toxicity. However, the complex
elationship between tumours and critical structures, with
oncave shapes and very close interrelation, limits the abil-
ty of conventional radiotherapy to shape the doses to the
arget volumes and to spare the organs at risk (OAR). In inten-
ity modulated radiation therapy (IMRT), modulation of the
eam ﬂuence permits to deliver a non-uniform intensity to
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the target,1 increasing the conformation of the high dose to
the tumour. The aim of this revision is to review the basis of
IMRT  and different methods to deliver this technology.
2.  Concept  of  IMRT  and  differences  with
3DCRT
The transition from conventional 2D treatment planning to 3D
conformal treatment (3DCRT) has been an important advance jesus.romero@salud.madrid.org (J.R. Fernández),
in radiation technology. In 3DCRT, simulation and planning are
performed based on computed tomography images, achiev-
ing a precise tumour deﬁnition and a more  accurate dose
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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calculation by accounting for axial anatomy and complex
tissue contours. Moreover, it permits to use multiple ﬁelds,
including oblique and non-coplanar, which together with vari-
ations in weight, wedges and shaped blocks or multileaf
collimators (MLC) permits to achieve adequate tumour cov-
erage and normal tissue sparing.
One of the main differences between IMRT  and 3DCRT is
the ability to conform the dose distribution to the target. In
most of the techniques to deliver IMRT,  MLC divides beam
ﬁelds in different segments, or creates “segments” moving
across the ﬁeld, getting a different ﬂuence in each beam. Mod-
ulation of the ﬂuence creates non-uniform spatial intensity
distributions that produce highly conformal dose distribu-
tions.
3.  Steps  involved  in  IMRT
Three of the most crucial parts of IMRT  are target delin-
eation, treatment planning and quality assurance. Because of
the resulting steeper absorbed-dose gradients, optimal IMRT
requires more  accurate delineation of both tumour and nor-
mal  tissue than does conventional radiotherapy. However,
there is a substantial heterogeneity in target deﬁnition and
prescription among radiation oncologists with IMRT exper-
tise that will make it difﬁcult to assess the success of the
treatment. Efforts to standardize and simplify the IMRT pro-
cess have been suggested for Head and Neck IMRT practice.2
Moreover, additional normal tissue often has to be delineated
because structures that are not speciﬁed are not considered
in the planning process, and may receive a signiﬁcant high
absorbed dose. Optimization is a key point in radiotherapy
planning. Using MLC, it is possible to create a wide range
of beam intensities employing different segments. Optimiza-
tion explores these possibilities to ﬁnd the optimum intensity
pattern for the desired outcome, that is speciﬁed with dose
and volume constraints. The planning process can be sum-
marized in three points: ﬁrst, the desired outcome is speciﬁed
in terms of dose and volume constraints and objectives for
OAR and PTV using a system of priorities. Second, an objec-
tive function will be constructed to specify the goodness of
the plan. During the optimization process, a candidate ﬂuence
distribution map  with a cost function as close as possible to
the objective function is searched. Finally, once the optimal
ﬂuence map  is found, it must be converted into deliverable
ﬁeld segments according to the speciﬁed method of deliv-
ery, considering the limitations of the treatment unit due to
physical and mechanical characteristics of the MLC. Dose cal-
culation algorithms based in beamlet optimization, such as
convolution/superposition (each ﬁeld is discretized into a grid
of beamlets with distinct intensity), or aperture-based opti-
mization (the best set of aperture shapes is found to deliver the
intensity pattern without discretization of the ﬁeld in beam-
lets), will provide accurate absorbed-dose calculations.34.  Image-guided  radiotherapy  (IGRT)
Delivery of a high radiation dose to the clinical target vol-
ume  avoiding critical structures increases the complexityiotherapy 1 8 ( 2 0 1 3 ) 371–375
of treatment planning and delivery and also the precision
required for localization and for securing geometrical preci-
sion. IMRT  has an excellent capability to put the dose where
it is needed on a screen. However, it is necessary to have in
mind that planning CT is a snap shot and may not represent
the every day location. The advent of on board cone beam com-
puted tomography (CBT) and in room CT with high soft tissue
contrast has opened new opportunities for higher accuracy
in radiotherapy.4 Other image-guidance capable systems that
have an important role in IGRT are ultrasonography, MRI, and
optical imaging techniques.5 Cone beam may be performed
before every fraction and corrections are made on line after
aligning with the planning CT, reducing both the systematic
and random position.6 Thus, the information derived could be
used to evaluate more  accurately the PTV margin required for
IMRT. Validated protocols of systematic error correction can
minimize the IGRT workload.7
Although supplementary imaging involved in IGRT exposes
the patient to more  radiation, with an extra dose of 0.1–3%
of the treatment total dose, this technique guarantees a pre-
cise administration of radiation at the right place. Moreover, a
reduction in the PTV margin will decrease the dose to critical
structures.8
Patients with head and neck cancer may experience signiﬁ-
cant changes in the tumour volume and anatomical structures
during the radiotherapy course. This issue has a special signif-
icance considering that IMRT achieves highly conformal dose
distributions. It has been shown that the tumour volume can
dramatically decrease during a treatment course, and that re-
planning considering this volume change would translate into
a substantial sparing of the surrounding critical structures.9
Moreover, patients treated also with chemotherapy may loose
considerable weight during their full radiation treatment, and
dose in critical structures may change as a result of this weight
loss.10 Image  guidance can allow to visualize the anatomical
changes during the treatment, and if dose distribution at some
point reveals that there are low dose regions or a higher dose
region in a critical structure, subsequent fractions could be
re-planned.
5.  IMRT:  clinical  or  dosimetric  beneﬁt?
Different retrospective studies have shown the increased ther-
apeutic ratio achievable with IMRT in tumours close to the
base of the skull, such as paranasal sinus cancer.11 One
of the most frequent chronic and invalidating side effects
in LAHNC is xerostomia, with a well documented associa-
tion with mean doses to the parotid gland of more than
26 Gy.12 Moreover, it has been recently shown that with
parotid doses lower than 25–30 Gy function recovery is sub-
stantial and a return to pre-treatment levels may be achieved
in 2 years after RT.13 A recent randomized study with 94
patients with locally advanced pharynx cancer has shown
that IMRT resulted in a decrease of xerostomia (Grade ≥ 2)
at 12 and 24 months compared with 3DCRT, with an abso-
lute beneﬁt of 54% at 24 months.14 IMRT allows to achieve
heterogeneous dose distributions and can be exploited to
treat simultaneously elective and primary volumes decreas-
ing the overall time of the treatment, with a potential
radio
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eneﬁt derived from reducing the impact of accelerated
roliferation. However, for efﬁcacy endpoints, there are no
obust data to advocate IMRT.15,16 High quality studies
re needed to determine the comparative effectiveness of
MRT.
There are potential disadvantages of IMRT that should
e considered. As a result of leakage and scattered radia-
ion, an IMRT  plan results in an increase in absorbed dose
utside the treated volume.17 It has been estimated that
he incidence of secondary malignancies may increase from
% to 1.75%,18 and it raises special concerns in paediatric
atients.19 However studies are needed to determine the
ncidence of second tumours compared with other tech-
iques. Some authors have claimed that recurrences may
resent in regions that would have been previously irradi-
ted with 3DCRT technique. However, different studies have
hown that despite the high conformality of dose distribu-
ions, geographical misses are uncommon.20 Finally, because
he resulting steep dose gradient, IMRT  involves more  accu-
ate delineation than conventional radiotherapy, and tissues
hat may receive unexpected high doses have to be contoured.
oreover, IMRT  has a more  stringent machine quality assur-
nce (QA) to check the performance of the IMRT delivery
ystem.21
IMRT  requires greater time and resource commitment than
onventional radiotherapy. Intensity modulated radiation
herapy employs automated iterative optimization techniques
hat take more  time than 3D-CRT treatment planning. More-
ver, IMRT  has more  stringent machine quality assurance to
heck the performance of the IMRT  delivery system.
.  Delivery  of  IMRT
odulation of intensity may be performed by MLC, a large
umber of highly absorbing tungsten leaves that can be moved
gainst each other to create a large variety of ﬁeld openings.22
he movement  of MLC  under a computer control can be used
o produce various forms of intensity modulation. Modulation
an be achieved by three main ways: IMRT with static ﬁeld
egments, IMRT  with dynamic delivery, and IMRT rotational
herapy. In IMRT  with static ﬁeld segments (step and shoot),
he ﬁeld is divided in different segments with uniform beam
evels, and radiation is not delivered while the leaves move to
reate the next segment.23 In dynamic IMRT  the radiation is
elivered as the leaves are moving. The leaves of MLC move
cross the ﬁeld, and the time-dependent position of each leaf
etermines the intensity.24 Finally, rotational therapy can be
elivered using intensity modulated arc therapy (IMAT) or
omotherapy. In the IMAT,  MLC  has the leaf pattern changing
ontinuously as the gantry rotates, allowing the simultaneous
ariation in dose rate.25 More  than one rotational arch with dif-
erent patterns of radiation can be required to get the optimal
istribution.25
Several investigations have compared dosimetric results of
MAT versus IMRT  with static ﬁelds. Most of the published data
ompare the different techniques in terms of target volume
overage, conformity index (the degree to which the high dose
egion conforms to the target volume), homogeneity index
uniformity of absorbed-dose distribution), monitor units andtherapy 1 8 ( 2 0 1 3 ) 371–375 373
time required to deliver the radiation. Results suggest that
both techniques are almost equivalent in volume coverage,
dose conformity and dose homogeneity, with a slight reduc-
tion with IMAT (VMAT, Elekta) in dose to OAR. Lee et al.26
compared the planning performance of IMAT  versus sequen-
tial IMRT for nasopharyngeal carcinoma, ﬁnding a similar
target coverage, with a 2% beneﬁt in sparing OAR with IMAT
(VMAT, Elekta). The major difference was the improved efﬁ-
ciency of IMAT,  resulting in a faster delivery time and the use
of fewer MU/fr. Stieler et al. compared IMRT  with 7 or 9 static
ﬁelds and IMAT (VMAT, Elekta), showing all plans to be of an
excellent quality in homogeneity, target coverage and confor-
mity. Again, the major difference was the higher efﬁciency
of VMAT, with faster delivery time (7.6, 8.5 and 4.3, respec-
tively) and the use of fewer MU/fr.27 Other investigations have
conﬁrmed these ﬁndings.28,29 It has to be considered that
results of comparisons between different techniques are per-
formed with speciﬁc conditions of linear accelerators, number
of beams and segments, and should not be generalized to
other treatment conditions.
7.  Tomotherapy
Helical tomotherapy (HT) is a combination of a compact 6 MV
linear accelerator, and a megavoltage computed tomogra-
phy (MVCT) detection system. A binary multileaf collimator
consisting of 64 leaves of 6.5 mm,  which can be “open” or
“closed”, generates multiple shaped beams called “beamlets”.
The length of time a leaf is in the open position determines
the intensity delivered by the “beamlet”. The dose is delivered
in a helical manner: the gantry continuously rotates while the
patient couch is translated in the rotation plane. The MVCT, as
other IGRT systems, can be used for patient setup and reposi-
tioning; visualization of tumoral or anatomical changes during
treatment, and reconstruction of the actual dose received by
the patient. Although MVCT images have a lower contrast
than KV-CT, their quality are sufﬁcient for setup veriﬁcation
and tumour identiﬁcation. Although the optimal frequency of
image registration has not been deﬁned, patient setup can be
improved if daily imaging is performed.30
The major components of the HT process comprise 3D
imaging generated by conventional CT; deﬁnitions of target
volumes and organs at risk (OARs); optimized HT planning;
creation of veriﬁcation data and phantom irradiation; transfer
of planning data to the treatment unit; pre-treatment MVCT;
corrections of patient setup if needed; treatment delivery; and,
optionally, dose reconstruction.
In head and neck cancer patients, mean treatment times
are longer for HT than in other modalities. In a report of Kruser
et al., the number of MU, varied signiﬁcantly between the
3DCRT (median = 502), step-and-shoot IMRT  (median = 1087),
and HT (median = 6757).31 Moreover, Head and Neck HT treat-
ment times have been reported in the range of 4.8–7.74 min;
longer than for Rapid-Arc, 1.4–3.05 min, and VMAT, 4.6 min.32
Several studies have reported the dosimetric characteris-
tics of tomotherapy and compared them with other IMRT
modalities. Helical tomotherapy may produce better homo-
geneous doses as compared with other IMRT  systems. A
dosimetric study demonstrate that both IMAT  (VMAT, Elekta)
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and HT are capable of providing more  uniform target doses
and improved normal tissue sparing as compared with ﬁxed
ﬁeld IMRT.33 In a comparison of HT with step-and-shoot
IMRT  for nasopharyngeal carcinoma, a signiﬁcant gain was
observed in the conformation index (CI) and homogeneity
index (HI) of 11.9% and 8.8%, respectively, favouring HT.34 In
others studies the conformity and homogeneity within the
PTV were improved for HT over IMAT  (VMAT, Elekta) and
IMRT.35
Due to its dose conformation capabilities, HT diminished
the dose received by the OARs, mainly by the parotid glands.
HT have signiﬁcantly better sparing of salivary glands than
segmental multileaf collimator (SMLC)-IMRT (mean dose of
27.3 vs. 34.1 Gy, p = 0.03).36 Another study conﬁrmed a lower
dose to the parotids for HT as compared with IMAT  (VMAT,
Elekta, and RapidArc, Varian Medical Systems) with doses of
14.1 Gy, 23 Gy and 26.5 Gy, respectively.37 In nasopharyngeal
carcinoma, compared to step-and-shoot IMRT,  HT reduced the
dose not only to parotids but also to brainstem (p = 0.02), larynx
(p = 0.03), and oral cavity (p = 0.03).38 Nguyen et al.39 reported a
mean total cochlea dose of 36 Gy for IMRT  compared to 12.1 Gy
for HT (p = 0.002) in patients with LAHNC. In a dosimetric anal-
ysis, HT reduced the maximum doses to the optic chiasm, as
well as to the ipsilateral optic nerve and retina as compared
with step-and-shoot IMRT (P < 0.05).40
There are a scarce number of non-randomized studies
reporting outcomes and normal tissue complications with HT.
The overall survival and loco-regional control for HT are simi-
lar to that reported in the literature for other IMRT  techniques
for oropharyngeal carcinoma41; sinonasal carcinoma 4242; oral
cavity43 and nasopharynx.34 Recently, a retrospective study
with a small number of patients has founded an increase in
recurrence free survival with HT compared to conventional
radiotherapy.44
8.  Conclusions
IMRT  creates non-uniform spatial intensity distributions to
achieve highly conformal dose distributions, decreasing doses
to OAR. However, no increase in survival or control has been
shown. There are different methods to deliver IMRT, with sim-
ilar advantages in conformality and homogeneity. The main
advantage of IMAT  is the shorter time to deliver a fraction of
radiation. Some studies have shown an advantage of HT in
conformality and homogeneity, with lower doses to organs at
risk. On the other hand, a longer treatment time has also been
described. The best method to deliver IMRT  depends on mul-
tiple factors, such as plan quality, deliverability, practicality,
user training, individual cases.
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